002868 Lifecome Biochemistry
- 13.40
- +1.22+10.02%
Lifecome Biochemistry News
Lifecome Biochemistry (002868.SZ) plans to raise no more than 80 million yuan through a simple program placement.
Lifecome Biochemistry (002868.SZ) announced the plan to issue stocks to specific targets in 2024 through a simplified procedure...
Lifecome Biochemistry: Announcement of Revised Performance Forecast for the First Half of 2024
Lifecome Biochemistry (002868.SZ): Shareholder Xiaohan intends to reduce her shareholding by no more than 1.73%.
Lifecome Biochemistry (002868.SZ) announced that Ms. Xiaohan holds 10,453,391 shares of the company's stock (6.73% of the total share capital) and intends to reduce the company's shares by no more than 2,682,600 shares (1.73% of the total share capital) through block trades within three months after 15 trading days from the date of the announcement of the reduction plan.
Lifecome Biochemistry: 2024 Interim Performance Forecast
Lifecome Biochemistry (002868.SZ): Expected to lose 50 to 65 million yuan in the first half of the year.
Lifecome Biochemistry (002868.SZ) announced the performance forecast for the first half of 2024. According to preliminary calculations by the finance department, it is expected to incur a net loss of 50-65 million yuan attributable to shareholders of the listed company in the first half of 2024, compared with a loss of 46.6652 million yuan in the same period last year. Deducting non-recurring gains and losses, the net loss is expected to be 85-98 million yuan, compared with a loss of 65.8977 million yuan in the same period last year. Basic loss per share is expected to be 0.32-0.42 yuan/share; operating revenue is expected to be 0.36-0.38 billion yuan, compared with 0.23 billion yuan in the same period last year.
Lifecome Biochemistry (002868.SZ): signed a supply agreement for methylene salicylic acid peptide with Solvay Biopharmaceuticals Belgium.
Lifecome Biochemistry (002868.SZ) announced on June 28 that it has signed a supply agreement for methylene salicylic acid peptide with Zoetis Belgium S.A. (referred to as “Zoetis”) for the years 2024 to 2026. The agreement covers the supply of methylene salicylic acid peptide for three years.
Lifecome Biochemistry (002868.SZ): Plans to transfer 100% equity of Wuhan Lifecome to Putan Thermal Energy for 27.3 million yuan.
On June 28th, Gelonhui announced that in order to focus on its main business, strengthen the management of business synergy of its subsidiaries, and further optimize its asset and business structure, Lifecome Biochemistry (002868.SZ) plans to transfer 100% equity of its wholly-owned subsidiary Wuhan Lifecome Bio-technology Co., Ltd. (hereinafter referred to as Wuhan Lifecome) to Fujian Putan Thermal Power Co., Ltd. (hereinafter referred to as Putan Thermal Power) for a transaction price of 27.3 million yuan. After the completion of the transaction, the company will no longer hold equity in Wuhan Lifecome, and Wuhan Lifecome will no longer be included in the company's consolidated financial statements. The transaction does not involve the target company.
Lifecome Biochemistry Names Chairman
Lukang Biochemical (002868.SZ): A biological preservative produced by microbial fermentation is being developed
Gelonghui, May 16, 丨 Lukang Biochemical (002868.SZ) held a performance briefing on May 15, 2024. Regarding “Please ask about your future plans for food additives,” the company replied that the natamycin series products currently produced by the company are mainly used for food preservation and preservation. Future product plans in the direction of food additives are developing biological preservatives produced using microbial fermentation.
Implementation of Lukang Biochemical (002868.SZ) related supervisors' and senior management holdings reduction plan completed
Lukang Biochemical (002868.SZ) issued an announcement. As of the disclosure date of this announcement, the company's supervisors and executives Feng Zhenwu,...
Lukang Biochemical (002868.SZ): Net loss of 31.3428 million yuan in the first quarter
Gelonghui, April 30, 丨 Lukang Biochemical (002868.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 160 million yuan, up 60.09% year on year; net profit attributable to shareholders of listed companies was 31.3428 million yuan, an increase in year-on-year losses; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 32.2093 million; and basic earnings per share - 0.2 yuan.
Benign Growth For Lifecome Biochemistry Co.,Ltd. (SZSE:002868) Underpins Stock's 28% Plummet
Lukang Biochemical (002868.SZ): The natamycin series products produced are mainly used for food preservation and preservation
Gelonghui March 26 | Lukang Biochemical (002868.SZ) said on the investor interactive platform that the natamycin series products produced by the company are mainly used for food preservation and preservation, and can be used in cheese, bread and pastries, braised meat products, fried meat, salad dressing, etc.
Lukang Biochemical (002868.SZ) plans to sell part of its assets located in Pudan Biological Professional Park to Putan Thermal Energy for 67.5 million yuan
Zhitong Finance App News, Lukang Biochemical (002868.SZ) announced that the company intends to sell some equipment fixed assets, building fixed assets and state-owned land use rights located in the Pudan Biological Professional Park in Pucheng County, Fujian Province. The transaction price is 67.5 million yuan (tax included). The details of this transaction are some equipment fixed assets, building-type fixed assets and state-owned land use rights located in Putan Biological Professional Park in Pucheng County, Fujian Province. Among them, there are 5 housing buildings, which are comprehensive housing, temporary storage workshops for sludge dehydration and drying, pharmacies, and hazardous waste
Revenues Not Telling The Story For Lifecome Biochemistry Co.,Ltd. (SZSE:002868) After Shares Rise 30%
Lifecome Biochemistry Co.,Ltd.'s (SZSE:002868) 26% Gain Last Week Benefited Both Private Companies Who Own 43% as Well as Insiders
Lukang Biochemical (002868.SZ): Pre-loss of 210 million yuan to 230 million yuan in 2023
Gelonghui, January 29丨Lukang Biochemical (002868.SZ) announced the 2023 annual results forecast, with operating income of 51 million yuan to 520 million yuan; net profit loss attributable to shareholders of listed companies of 21 million yuan to 230 million yuan, loss of 121.94 million yuan in the same period last year; net profit loss after deducting non-recurring profit and loss of 225 million yuan to 250 million yuan; loss of 123.21 million yuan for the same period last year; basic earnings loss per share of 1.35 yuan/share — 1.48 yuan/share. During the reporting period, the company's operating income compared to the same period last year
Lifecome Biochemistry Co.,Ltd.'s (SZSE:002868) Shares Climb 31% But Its Business Is Yet to Catch Up
Does Lifecome BiochemistryLtd (SZSE:002868) Have A Healthy Balance Sheet?
Lukang Biochemical (002868.SZ): Some supervisors and executives plan to reduce their holdings by no more than 161,000 shares
Gelonghui, January 12 | Lukang Biochemical (002868.SZ) announced that shareholder Feng Zhenwu directly held 115,725 shares of the company (0.07% of the company's total share capital) to reduce his holdings of the company's shares by no more than 28,931 shares (0.019% of the company's total share capital) through centralized bidding transactions (excluding the period where holdings reduction is prohibited according to relevant laws and regulations) within 3 months after the announcement of the capital reduction plan. Shareholder Lou Lijun directly held 55,282 shares of the company (accounting for 0.04% of the company's total share capital) and traded 15 shares since the date of the announcement of the capital reduction plan
Analysis
Price Target
No Data
